Rare diseases pose a particular challenge for drug developers: small patient populations, thin evidence bases, and diagnostic paths that historically led clinicians astray. Blastic plasmacytoid dendritic cell neoplasm, or BPDCN, is a case in point — a rare and aggressive hematologic malignancy, derived from precursor plasmacytoid dendritic cells, that primarily affects the skin, bone...